AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.15+0.00 (+0.13%)
Close on Nov 12, 2026Market cap $4.52MP/E –Yield –
AIM ImmunoTech r&d expenses
Research and development expenses are spending on new products and technology.
AIM ImmunoTech's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.98M, down 34.1% year over year. For fiscal 2025 it was $3.92M, down 36.7% from the year before. Over ten years it grew -6.9% a year on average. The highest annual figure on record is $10.94M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.92M | -36.7% |
| FY2024 | Dec 31, 2024 | $6.20M | -43.3% |
| FY2023 | Dec 31, 2023 | $10.94M | +56.5% |
| FY2022 | Dec 31, 2022 | $6.99M | -8.9% |
| FY2021 | Dec 31, 2021 | $7.67M | +34.1% |
| FY2020 | Dec 31, 2020 | $5.72M | +23.0% |
| FY2019 | Dec 31, 2019 | $4.65M | -2.7% |
| FY2018 | Dec 31, 2018 | $4.78M | +16.6% |
| FY2017 | Dec 31, 2017 | $4.10M | -19.8% |
| FY2016 | Dec 31, 2016 | $5.11M | -36.5% |
| FY2015 | Dec 31, 2015 | $8.04M | -10.6% |
| FY2014 | Dec 31, 2014 | $8.99M | +7.5% |
| FY2013 | Dec 31, 2013 | $8.36M | -12.1% |
| FY2012 | Dec 31, 2012 | $9.51M | +41.4% |
| FY2011 | Dec 31, 2011 | $6.72M | -11.7% |
| FY2010 | Dec 31, 2010 | $7.61M | +8.8% |
| FY2009 | Dec 31, 2009 | $7.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $846.00K | +39.4% |
| Q2 FY2026 | Jun 30, 2026 | $589.00K | -49.8% |
| Q1 FY2026 | Mar 31, 2026 | $482.00K | -55.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.06M | -36.1% |
| Q3 FY2025 | Sep 30, 2025 | $607.00K | -57.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.17M | +2.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.08M | -44.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.66M | -48.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.44M | -47.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.15M | -45.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.95M | +42.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.20M | +29.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.73M | +163.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.11M | -27.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.37M | -31.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.48M | +87.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.04M | -27.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.92M | +28.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.01M | +82.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.32M | -10.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.42M | +58.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.28M | +58.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.10M | -7.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.46M | +33.5% |
| Q1 FY2020 | Mar 31, 2020 | $898.00K | -3.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.44M | +45.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.19M | -25.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.10M | -18.3% |
| Q1 FY2019 | Mar 31, 2019 | $928.00K | +8.5% |
| Q4 FY2018 | Dec 31, 2018 | $987.00K | +21.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.60M | +102.7% |
| Q2 FY2018 | Jun 30, 2018 | $1.34M | +21.2% |
| Q1 FY2018 | Mar 31, 2018 | $855.00K | -38.5% |
| Q4 FY2017 | Dec 31, 2017 | $814.00K | -56.3% |
| Q3 FY2017 | Sep 30, 2017 | $787.00K | -41.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.86M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.34M | – |
See a number that looks wrong?